STAT4d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
pharmaphorum2d
Novo Holdings leads $100m round for novel painkiller biotech
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...
MM&M4d
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
FierceBiotech2d
Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...
Catalent Acquired by Novo Holdings in $16.5 Billion Deal
The latest announcement is out from Catalent ( (CTLT) ).
Novo Holdings Completes Acquisition of Catalent
Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment ...
Barron's on MSN3d
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...